Literature DB >> 22411722

Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations.

Chethan Sampath1, Karin Haug, Sophia Thanei, Matthias Hamburger, Hartmut Derendorf, Reginald Frye, Veronika Butterweck.   

Abstract

Valerenic acid (VA), a sesquiterpenoid, is one of the major secondary bioactive metabolites of VALERIANA OFFICINALIS L. Until now IN VIVO studies on the absorption, bioavailability, disposition, and metabolism of VA are limited. We established and validated an LC-MS/MS assay for the determination of VA in rat plasma and successfully used this method for pharmacokinetic studies in rats after intravenous (i. v.) and oral administrations. The plasma concentration-time data was analyzed by both non-compartmental and compartmental approaches using WinNonlin software. Following i. v. administration, the disposition of VA in rat plasma was biphasic, subdivided into a fast distribution and a slow elimination phase. The half-life of the distribution phase was 6-12 min, and that of the terminal elimination phase 6-46 h, indicating a possible large tissue binding. Disposition PK of valerenic acid after oral treatment was also described by a two-compartment model with a clearance (CL/F) of 2-5 L · h (-1) · kg (-1) and volume of distribution of (V (d)) 17-20 L · kg (-1). The extent of absorption (F) after oral administration was estimated to be 33.70 % with a half-life of 2.7-5 h. Dose proportionality was observed in terms of dose and AUCs, suggesting linear pharmacokinetics at the dose levels studied in rats. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22411722     DOI: 10.1055/s-0031-1298301

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  6 in total

1.  Valerenic Acid Protects Against Physical and Psychological Stress by Reducing the Turnover of Serotonin and Norepinephrine in Mouse Hippocampus-Amygdala Region.

Authors:  Hyo Young Jung; Dae Young Yoo; Sung Min Nam; Jong Whi Kim; Jung Hoon Choi; Miyoung Yoo; Sanghee Lee; Yeo Sung Yoon; In Koo Hwang
Journal:  J Med Food       Date:  2015-07-15       Impact factor: 2.786

Review 2.  Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.

Authors:  Josh Lister; José N Nobrega; Paul J Fletcher; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2014-04-22       Impact factor: 4.530

3.  Esters of valerenic acid as potential prodrugs.

Authors:  Juliane Hintersteiner; Maximilian Haider; Denise Luger; Christoph Schwarzer; Gottfried Reznicek; Walter Jäger; Sophia Khom; Marko D Mihovilovic; Steffen Hering
Journal:  Eur J Pharmacol       Date:  2014-03-27       Impact factor: 5.195

4.  The anxiolytic effects of a Valerian extract is based on valerenic acid.

Authors:  Axel Becker; Falko Felgentreff; Helmut Schröder; Beat Meier; Axel Brattström
Journal:  BMC Complement Altern Med       Date:  2014-07-28       Impact factor: 3.659

5.  Analysis of β-Subunit-dependent GABAA Receptor Modulation and Behavioral Effects of Valerenic Acid Derivatives.

Authors:  S Khom; J Hintersteiner; D Luger; M Haider; G Pototschnig; M D Mihovilovic; C Schwarzer; S Hering
Journal:  J Pharmacol Exp Ther       Date:  2016-04-18       Impact factor: 4.030

6.  Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial.

Authors:  Afshin Samaei; Monir Nobahar; Zaynab Hydarinia-Naieni; Abbas Ali Ebrahimian; Mohammad Reza Tammadon; Raheb Ghorbani; Abbas Ali Vafaei
Journal:  BMC Nephrol       Date:  2018-12-27       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.